Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase FinancialNewsMedia - Mon Jun 17, 8:45AM CDT

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 6.96 (-3.33%)
BPTH : 1.8600 (-4.12%)
LGVN : 1.6800 (+7.01%)
SLS : 1.1200 (-5.08%)
BMY : 40.45 (-2.06%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase GlobeNewswire - Mon Jun 17, 8:45AM CDT

ATNM : 6.96 (-3.33%)
BPTH : 1.8600 (-4.12%)
LGVN : 1.6800 (+7.01%)
SLS : 1.1200 (-5.08%)
BMY : 40.45 (-2.06%)
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call Investor Brand Network - Fri May 3, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase Investor Brand Network - Mon Apr 29, 9:28AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2,...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering Investor Brand Network - Mon Apr 22, 10:22AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M Investor Brand Network - Thu Apr 18, 9:30AM CDT

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M Investor Brand Network - Mon Apr 15, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering Investor Brand Network - Wed Apr 10, 8:37AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update Investor Brand Network - Mon Apr 1, 9:36AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 1.6800 (+7.01%)
Longeveron (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split Investor Brand Network - Thu Mar 21, 9:03AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock....

LGVN : 1.6800 (+7.01%)

Barchart Exclusives

Is This Copper Mining Stock a Buy for Its Fat Dividend? Barchart - Tue Jul 2, 6:30PM CDT
Southern Copper has a higher dividend yield compared to other copper mining companies. However, its valuations are also on the higher side, making a closer examination of the risk-reward necessary for prospective investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot